FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
The well-known cannabis-based pharmaceutical drug Epidiolex, primarily used to treat childhood epilepsy, may offer relief to veterans suffering from Gulf War Illness (GWI), according to new research.
A new study on rats shows the potential of Epidiolex, the FDA-approved cannabidiol (CBD) drug produced by Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)’s GW Pharmaceuticals, in addressing cognitive, mood and pain-related symptoms of GWI, a condition linked to chemical exposures during the 1990-1991 Gulf War.
The research, conducted by Chinese scientists, was first reported by Hemp Today.
Cognitive And Pain Improvements Observed
The research, published in Military Medical Research, reveals that long-term oral administration of CBD could alleviate cognitive impairments, mood disorders and chronic pain.
Rats treated with Epidiolex showed significant improvements in object recognition and memory retention, which are common areas of dysfunction in veterans with GWI. Additionally, CBD treatment helped …